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Abstract
Tab2, originally described as a component of the inflammatory pathway, has been impli-
cated in phenomena of gene de-repression in several contexts, due to its ability to interact
with the NCoR corepressor. Tab2 interacts also with steroid receptors and dismisses NCoR
from antagonist-bound Estrogen and Androgen Receptors on gene regulatory regions, thus
modifying their transcriptional activity and leading to pharmacological resistance in breast
and prostate cancer cells. We demonstrated previously that either Tab2 knock-down, or a
peptide mimicking the Estrogen Receptor alpha domain interacting with Tab2, restore the
antiproliferative response to Tamoxifen in Tamoxifen-resistant breast cancer cells. In this
work, we map the domain of Tab2 responsible of Estrogen Receptor alpha interaction. First,
using both co-immunoprecipitation and pull-down with recombinant proteins, we found that
the central part of Tab2 is primarily responsible for this interaction, and that this region also
interacts with Androgen Receptor. Then, we narrowed down the essential interaction region
by means of competition assays using recombinant protein pull-down. The interaction motif
was finally identified as a small region adjacent to, but not overlapping, the Tab2 MEKK1
phosphorylation sites. A synthetic peptide mimicking this motif efficiently displaced Tab2
from interacting with recombinant Estrogen Receptor alpha in vitro, prompting us to test its
efficacy using derivatives of the MCF7 breast carcinoma cell lines that are spontaneously
resistant to Tamoxifen. Indeed, we observed that this mimic peptide, made cell-permeable
by addition of the TAT minimal carrier domain, reduced the growth of Tamoxifen-resistant
MCF7 cells in the presence of Tamoxifen. These data indicate a novel functional domain of
the Tab2 protein with potential application in drug design.
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Introduction
The Tab2 protein (also known as TGF-β activated kinase 1/MAP3K7 binding protein 2) has
been implicated in the mechanisms of resistance to steroid antagonists in breast and prostate
cancer, contributing an additional piece of the jigsaw to the long-standing concept of cross-
talk between inflammation and hormonal response, as well as between inflammation and can-
cer. Indeed, the Tab2 protein was originally described as a component of the TNFα/TGF-β
and inflammatory cytokines transduction pathways [1,2]. Tab2 was firstly identified as an
adaptor protein in the cytoplasm linking TAK1 and TRAF6 in the interleukin-1β (IL-1β) sig-
naling pathway [1], suggesting that activation of the NF-kB and MAPK cascades by IL-1β
involves the formation of a TRAF6-Tab2-TAK1 complex. In this complex, TRAF6 is autopo-
lyubiquitinated with Lys-63-linked ubiquitin chains, through which it interacts with Tab2,
leading to the binding and activation of TAK1 and subsequently the activation of IKK and
NF-kB [3]. Thus, Tab2 ubiquitination mediated by TRAF6 appears to play an important role
in TAK1 activation in IL-1β signal transduction [4].
In addition to its role as adaptor in the cytokine signaling pathway, Tab2 displays regulatory
roles in transcriptional repression, in conjunction with the NCoR corepressor complex, in dif-
ferent contexts such as NF-kB regulated genes [5], astrocyte-specific genes in neuronal precur-
sors [6] and prostate and breast cancer cells, where Tab2 mediates reversion of steroid
receptor antagonists effects in response to inflammation [7,8].
First, in neurodegeneration a model has been proposed, in which Tab2 is recruited to NF-
kB regulated genes by an interaction with the Bcl3 protein, acting as a bridge linking NF-kB to
nuclear coregulators [5]. In response to IL-1β signaling, the stable Tab2/HDAC3/NCoR core-
pressor complex, bound to p50 target genes, undergoes translocation to the cytoplasm, result-
ing in the recruitment of Tip60-containing coactivator complex on NF-kB target genes. In this
model, Tab2 has a dual role in response to IL-1β: it acts both to contribute to de-repression of
p50-dependent transcription unit (its nuclear action) and to activate the NF-kB pathways (its
cytoplasmic function), as previously demonstrated by Takaesu et al. [1].
The second context, proposed by Sardi and colleagues, involved the regulation of the timing
of astrogenesis in the developing brain [6]. The E4ICD cytoplasmic domain of ErbB4, released
by presenilin after activation by the ligand neuregulin-1, is able to interact with Tab2 in a spe-
cific manner and this is dependent on the tyrosine kinase activity of the ErbB4 fragment. Tab2,
acting as an adaptor molecule, forms a ternary E4ICD/Tab2/NCoR complex that could be
detected in lysates from neuregulin-1-stimulated cells. This complex undergoes translocation
to the nucleus, where it targets several glial genes to transcriptional repression, which is
required for the differentiation of neuronal precursor cells into astrocytes.
The third model involves the interaction between Tab2 and the Androgen Receptor (AR)
or the Estrogen Receptor alpha (ERα) in mediating reversion of steroid receptor antagonists
effects in response to inflammation [7,8]. Studies on antiandrogen-resistant prostate cancer
cells showed that IL-1β induces phosphorylation of Tab2 engaged in the nucleus with NCoR
complexes, allowing Tab2 to translocate to the cytoplasm together with NCoR, thus dismissing
repression from androgen responsive genes and functionally converting antiandrogenic com-
pounds to androgenic [7]. In response to IL-1β, the MAPK kinase kinase 1 (MEKK1) phos-
phorylates Tab2, unmasking its nuclear export signal sequence (NES). Thus, the NCoR/Tab2
complex is dismissed from AR, and coactivators can associate, instead. As a consequence, the
antiandrogenic drug Bicalutamide is switched from repressing AR transcriptional activity to
stimulating it [7]. Interestingly, suppression of Tab2 resulted in reversal of IL-1β effect, dem-
onstrating that Tab2 is not essential to transcriptional repression by AR. A similar mechanism
was observed in MCF7 breast cancer cells in response to Tamoxifen (Tam). Tab2 is recruited
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to ERα- or AR-responsive genes through interaction with an L/HX7LL conserved motif in the
N-terminal domain of sex steroid receptors proteins (AR, ERα, and Progestin receptor (PgR)).
A peptide mimicking this region reverts IL-1β induced NCoR dismissal when microinjected in
prostate cancer cell nuclei [7].
We demonstrated previously that spontaneously Tam-resistant (TamR) derivatives of the
MCF7 breast carcinoma cell line have constitutively phosphorylated Tab2, and knocking-
down Tab2 expression by siRNA is sufficient to restore the antiproliferative response to Tam
[8], thus implying constitutive activation of Tab2 in endocrine resistance. A region in the cen-
tral part of Tab2 (CC domain and adjacent regions, see below) contain several Serines and Tyr-
osines that can be phosphorylated through different pathways, involving MEKK1 and p38 in
response to cytokines and EGF [5,9–11]. Moreover, mutations of the MEKK1 gene were also
found associated to resistance to aromatase inhibitors [12], involving Tab2 in a more general
mechanism of pharmacological resistance. We have also shown that a cell-permeable peptide
mimicking aa. 4–17 of hERα [7] abrogates Tab2/ERα interaction in vitro and restores Tam
response in TamR cells [8].
The interaction between Tab2 and NCoR has been roughly mapped: it involves the repres-
sor domain I of NCoR and the N-terminal region of Tab2 (aa 1–628) [5,6]. Tab2 (and its
closely related protein Tab3) contain an N-terminal CUE domain (Cue1-homolog) that
includes Phenylalanine and Proline (FP) residues essential for the direct binding of monoubi-
quitin. In the C-terminal half, other characterized parts include a coiled-coil domain (CC),
involved in the interaction with TAK1, and a zinc-finger (NZF) domain also called nuclear
protein localization 4 (Npl4) or zf-RanBP domain, involved in polyubiquitin binding [13].
Tab2 and Tab3 bind preferentially to lysine 63-linked polyubiquitin chains through this highly
conserved NZF domain, and in fact mutations to NZF abrogate polyubiquitin chain binding
together with Tab2/Tab3 ability to activate TAK1 and IKK [14].
Although Tab2 interaction with ERα and AR has been clearly established [7,8], very little is
known about the Tab2 domain involved, with the exception of its rough localization to the
C-terminal half. More detailed mapping would be an important issue, because it will help
shedding light on the exact mechanism of Tab2 recruitment and dynamics within the core-
pressor complex. Tab2 acts as “molecular beacon” integrating nuclear transcriptional response
of different signaling pathways and impinges upon molecular mechanisms that are relevant
for clinics and pharmacological intervention, as exemplified by Tam or Bicalutamide or the
neurodegenerative context.
In this paper we describe the fine mapping of Tab2 domain involved in ERα interaction
and show that a cell-permeable mimic peptide can reverse Tam resistance in MCF7-TamR
cells in culture.
Materials and Methods
Chemicals and antibodies
4-hydroxytamoxifen (4OHT) was purchased from Sigma-Aldrich. Polyclonal anti-ERα anti-
body (H-184), anti-MBP (C-18) and anti-NFkB-p65 antibodies were from Santa Cruz Biotech-
nology. Monoclonal antibody anti-Flag and polyclonal antibody anti-Tab2 (491–505) were
from Sigma-Aldrich. Polyclonal anti-epitope T7 antibody was purchased from Abcam.
Recombinant human ERα was purchased from Life Technologies. The Tab2 peptides were
synthesized by microwave-assisted synthetic protocols and their analysis and purification were
carried out by analytical and semi-preparative reversed phase high performance liquid chro-
matography (RP-HPLC). The TAT-Tab2 peptides were purchased from the Peptide Facility of
CRIBI (Biotechnology Center) in Padua, Italy.
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Plasmids, mutants and fragments
The pCMV-T7 containing the full length hTab2 cDNA, the p3XFLAG-CMV containing the
hAR cDNA and the pGEX-JDK containing hERα (1–45) were generous gifts from Prof. MG
Rosenfeld (UCSD, La Jolla, CA). The hERα expression vector pHEGO and the
p3XFLAG-CMV containing the hERα cDNA were generous gifts from Prof. P. Chambon
[15] and Prof. A Weisz (University of Naples, Italy), respectively. The cDNA encoding hERα
(1–60) was amplified by PCR and cloned into pCMV-p65 vector. The cDNA encoding human
Tab2 full-length and all the Tab2 fragments (Δ CUE Tab2, Δ sinoS Tab2, 406-531Tab2, Δ NZF
Tab2, Δ NZFCC Tab2, Δ NZFCCSS Tab2, and 1–350 Tab2) were amplified by PCR and cloned
into pMALc2 vector. All constructs were verified by automated DNA sequencing. The cDNAs
encoding the 6 partially overlapping fragments whose sequence has been designed on the
sequence of the Tab2 central fragment 406–531 (Table 1) were amplified by PCR and used to
in vitro transcribe and translate (TnT) all fragments using the TNT1 T7 Quick Coupled Tran-
scription/Translation System (Promega). The T7 promoter sequence was added 5’ to all for-
ward primers to allow transcription.
Cell lines and treatments
Tamoxifen-resistant cells were obtained by continuous passage of MCF7 in the presence of sub-
lethal doses of Tamoxifen [16]. For the experiments, we used two independent subcultures
from MCF7/TAMR-4 (independently passaged>15 times), here indicated as TAMR-4.1 and
TAMR-4.2, and the MCF7/TAMR-8 cell line, indicated as TAMR-8. Resistant cells, collectively
called TamR, were continuously propagated in phenol red-free DMEM/F12 1:1 (Life Technolo-
gies), supplemented with 1% FBS (Biochrom, S0115-1) and 10−6 M 4OHT. For proliferation
assays, TamR cells were plated at 1 x 104 cells/well in 96-well plates in phenol red-free DMEM
+ 10−6 M 4OHT in the absence of FBS, then were treated for 24 hours with the appropriate con-
centrations of peptides, as described below. Proliferation was measured by two-hours bromo-
deoxyuridine incorporation (Cell Proliferation Biotrak ELISA System kit, GE-Healthcare,
RPN20) followed by chemi-luminescence detection on a Bio-Rad Benchmark plus
spectrophotometer.
Table 1.
Fragments (Fr) Primers
Fr1 Fw 5’-TAATACGACTCACTATAGGGATGTCCACAAACTCTGGAGCATCT-3’
Rv 5’-TGCCTATTGCTCGACTTTTG-3’
Fr2 Fw 5’-TAATACGACTCACTATAGGGATGGGTCCTGCCTTTATTCA-3’
Rv 5’-TTTCGTATTGGGCTGAGTGA-3’
Fr3 Fw 5’-TAATACGACTCACTATAGGGATGACCTCTCCTCGAGTGGTAGTCA-3’
Rv 5’-ACACCACCCCTGGTGAAACT-3’
Fr4 Fw 5’-TAATACGACTCACTATAGGGATGAATAAGCCCCCTGCAGTTTC-3’
Rv 5’-TGCTGAATATTCTCGGTTTCTACA-3’
Fr5 Fw 5’-TAATACGACTCACTATAGGGATGGTAGAAACCGAGAATATTCAGCAC-3’
Rv 5’-GCAGCATCATCAGATCCCATA-3’
Fr6 Fw 5’-TAATACGACTCACTATAGGGATGCCACTGCTTACTGGCTTATCG-3’
Rv 5’-ATAAAGGCAGGACCCATGCT-3’
doi:10.1371/journal.pone.0168639.t001
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Cell transfection
HEK293T cells were plated at 15 x 105 cells/plate in 10020mm plates and after 18 hours later
transfected with either i) 6 μg pCMV-T7-Tab2(406–531) and 6 μg pCMV-p65-ERα(1–60); or
ii) 6 μg pCMV-T7-Tab2(406–531) and 6 μg p3XFLAG-CMV-ERα full-length; or iii) 6 μg
pCMV-T7-Tab2(406–531) and 6 μg p3XFLAG-CMV-AR full-length, using LipofectA-
MINE2000 (LifeTechnologies) according to the manufacturer’s instructions. After 4 hours, the
medium was changed to high glucose DMEM supplemented with 10% FBS and cells harvested
24 hours later.
Treatment with peptides
The TAT-Tab2-pept3 or scrambled TAT-Tab2-pept3 peptides, at concentrations ranging
from 1 μM to 100 μM, were added to TamR cells in phenol red-free DMEM + 10−6 M 4OHT
in the absence of FBS, due to the low stability of the peptide in serum. After 1 hour, 1%
DC-FBS was added.
Co-immunoprecipitation, pull-down and immunoblotting
Co-immunoprecipitations of ERα and Tab2 or AR and Tab2 were carried out from total cell
lysates of HEK293T cells. HEK293T cells were lysed with RIPA Buffer (150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 2 mM EDTA, 50 mM NaF,
1X PIC, 1 mM PMSF) put on ice 30 min and centrifuged at 12,000xg for 10 min. Supernatants
were diluted in RIPA Buffer without SDS. 15 μg of anti-NFkB-p65 antibody or 15 μg of anti-
epitope T7 antibody were used. The samples were incubated overnight at 4˚C, then 50 μL of
protein A sepharose beads in RIPA Buffer without SDS were added, and incubation continued
for another 2 hours. The pellet was washed 1 time in LiCl Buffer (0.25 M LiCl, 1% NP40, 1%
Na DOC, 1mM EDTA, 10mM Tris-HCl pH8), 1 time in RIPA Buffer without SDS and 2 times
in CoIP Buffer (20 mM Hepes pH 7.9, 10% glycerol, 5 mM MgCl2, 0.2 mM EDTA, 1 mM
DTT, 0.1% NP-40, 1 mM PMSF, 50 mM NaF, 1X PIC). The samples were analyzed by immu-
noblotting with the appropriate antibodies.
For in vitro pull-down assays, purification of MBP-fusion proteins (MBP-Tab2 full-length,
MBP-Δ CUETab2, MBP-ΔsinoSTab2, MBP-406-531Tab2, MBP-ΔNZFTab2, MBP-
ΔNZFCCTab2, MBP-ΔNZFCCSSTab2, and MBP-1-350Tab2) and GST-ERα (1–45) protein
were performed according to manufacturers’ protocol (General Healthcare). Pull-down assay
described in Fig 1b was done using MBP-Tab2 proteins and ERα-overexpressing HEK293T
cell lysates. HEK293T cell lysate was prepared by adding 300 μl of Lysis Buffer 1X (150 mM
NaCl, 2 mM Tris/HCl pH 7.8, 2 mM EDTA, 0.5% NP-40, 2 mM Na3VO4, 1X PIC, 1 mM
PMSF). MBP-Tab2 fusion constructs (10 μg) were incubated in pull-down buffer (125 mM
NaCl, 20 mM Tris/HCl pH 7.8, 10% glycerol, 0.1% NP-40, 0.5 mM DTT, 1X PIC, 1 mM
PMSF) with HEK293T cell lysate for 1.5 hours at 4˚C under rotation. A volume of 50 μl of pre-
washed Amylose Resin beads was then added for 1 hour at 4˚C on rotation.
Pull-down assay described in Fig 1c was performed using MBP-Tab2 proteins, in vitro
translated and transcribed Tab2(406–531) and ERα-overexpressing HEK293T cell lystes. 10 μg
MBP-Tab2 fusion constructs (MBP-Tab2 full-length, MBP-ΔsinoSTab2 and MBP-Tab2(406–
531)) were preincubated in pull-down buffer with 5 μl in vitro translated and transcribed
Tab2(406–531) for 1 hour on rotation at 4˚C and then mixed with HEK293T cell lysate for 1.5
hours at 4˚C under rotation. A volume of 50 μl of prewashed Amylose Resin beads was then
added for 1 hour at 4˚C on rotation.
Pull-down described in Fig 2a was done using GST-ERα (1–45) and in vitro translated and
transcribed Tab2(406–531). 10 μg GST-ERα (1–45) or GST alone were incubated in pull-
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Fig 1. The central domain of Tab2 contains the major determinants of Tab2/ERα interaction. a. Scheme of Tab2
fragments of different length expressed in bacteria as MBP fusion proteins. The functional domains are indicated as
follows: the CUE domain, the CC (coiled coil) domain including the nuclear export sequence, the NZF (novel zinc finger)
domain and the sequence (II) containing two phosphorylation sites (S419 and S423). b. MBP pull-down assays, using
ERα-overexpressing HEK293T cell lysate and MBP-Tab2 fusion proteins described in a). The loading control for all Tab2
fragments is provided in S1 Fig. c. MBP pull-down assays using the MBP fusion proteins Tab2 full-length, ΔsinoSTab2
and Tab2(406–531) as a control, and ERα-overexpressing HEK293T cell lysates in the presence or not of the in vitro
transcribed and translated Tab2(406–531) fragment. The lower bands represent the total amount of MBP-Tab2 fusions
present in the assay.
doi:10.1371/journal.pone.0168639.g001
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Fig 2. The central domain of Tab2 interacts with the conserved N-terminal domain of ERα and AR. a.
GST pull-down assay using the ERα fragment encompassing aa 1–45 expressed as GST fusion protein and
the in vitro transcribed and translated Tab2(406–531). b,c,d. Co-immunoprecipitation of T7-tagged Tab2(406–531)
and (b) p65-tagged ERα(1–60); (c) Flag-tagged full-length ERα; (d) Flag-tagged full-length AR. The plasmids
were transiently overexpressed in HEK293T cells, as follows: p65-ERα(1–60) plus T7-Tab2(406–531); Flag-full-
length ERα (f.l.) plus T7-Tab2(406–531); Flag-full-length AR (f.l.) plus T7-Tab2(406–531). Mock transfected cells
are untransfected cells. Anti-p65 and anti-T7 immunoprecipitates were carried out from total cell lysates and
were analyzed by western blot with anti-ERα, anti-Flag and anti-T7 antibodies.
doi:10.1371/journal.pone.0168639.g002
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down buffer with 5 μl in vitro translated and transcribed Tab2(406–531) for 2 hour on rotation
at 4˚C. A volume of 50 μl of prewashed Glutathione Resin beads was then added for 1 hour at
4˚C on rotation.
Pull-down assays described in Fig 3a and 3b were performed using MBP-Tab2(406–531),
Tab2 peptides and recombinant hERα. 10 μg MBP-Tab2(406–531) were preincubated in pull-
down buffer with 10 μM each Tab2-pept1, Tab2-pept2, Tab2-pept3 or with increasing concen-
tration (100 nM to 10 μM) of Tab2-pept3 for 1 hour on rotation at 4˚C and then mixed with
recombinant hERα (1 nM) for 1.5 hours at 4˚C under rotation. A volume of 50 μl of prewashed
Amylose Resin beads was then added for 1 hour at 4˚C on rotation.
In all pull-down assays, the protein complexes were washed 3 times with pull-down buffer,
recovered by centrifugation at 12,000xg, resuspended in SDS-gel loading buffer and analyzed
by immunoblotting with the appropriate antibodies.
Statistical analysis
Single-point data significance was evaluated using T-test for paired, two-tailed statistics. For
dose-response curves, a generalized least square regression model was used to ascertain
whether a significant interaction occurred between wild type/scrambled peptides and time,
with respect to cell proliferation. A correlation structure was specified to account for measures
at different dose levels over repeated experiments. A continuous-time autoregressive of order
1 (CAR1) correlation structure resulted the best model fit, based on AIC values. Non-linear
dose-response relationship was tested using Wald test.
Fig 3. A Tab2 mimic peptide displaces the Tab2/ERα interaction. a. Aminoacid sequences of the three synthetic partially
overlapping 17-aa each peptides, corresponding to different portions of the Fragment 4 described in S2 Fig. (here called
Tab2-pept1, Tab2-pept2 and Tab2-pept3). b. MBP pull-down assays, using MBP-Tab2(406–531), recombinant hERα (1 nM) and the
three different synthetic Tab2 peptides (at a concentration of 10 μM each). c. Dose-response curve on pull-down assays, using
MBP-Tab2(406–531), recombinant hERα (1 nM) and the Tab2-pept3 at concentrations ranging from 0 to 10 μM.
doi:10.1371/journal.pone.0168639.g003
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Results
The central domain of Tab2 contains the major determinants of
Tab2/ERα interaction
Interaction of ERα with a Tab2 fragment comprising aa. 406–531 (Tab2(406–531)) was shown
previously [8]. However, we wanted to evaluate if this “central” domain contains the major
determinants of this interaction. In order to obtain this information, we designed a series of
fragments of Tab2 of different length containing, or deleted of, the following functional
domains: the CUE domain (aa 8–50); the CC domain (aa 530–615) including the nuclear
export sequence; the NZF domain (aa 663–693); and the sequence containing the two Serines
(S419 and S423) identified as phosphorylation sites for MEKK1 [5] (Fig 1a). These fragments
were expressed in bacteria as MBP fusion proteins and tested in pull-down assays. We
observed that full-length Tab2, as expected, and all the fragments retaining at least part of the
C-terminus, up to the critical regulatory MEKK1 phosphorylation sites (S419 and S423),
pulled-down in a very efficient manner ERα from lysates of overexpressing HEK293T cells,
whereas mutants lacking this domain did not (Fig 1b). Loading controls for this experiment
are provided as S1 Fig. To further confirm the importance of this domain, we constructed a
fragment containing only the central part of Tab2 (Tab2(406–531)), which showed strong inter-
action with ERα (Fig 1b). Next, we expressed Tab2(406–531) by in vitro transcription and trans-
lation and used it in competition assays including ERα from lysates of overexpressing
HEK293T cells and MBP fusion proteins Tab2 full-length, ΔsinoSTab2 and itself as a control
(Fig 1c). Even though the MBP fusions were quite different in the different conditions, we can
conclude that Tab2(406–531) is very efficient in competing these interactions. Taken together,
these results confirm that the domain of Tab2 spanning aa. 406–531 is likely to contain the
major determinants of ERα interaction.
The central domain of Tab2 interacts with the conserved N-terminal
domain of ERα and AR
Next, we asked whether the fragment of ERα encompassing aa 1–45, containing the conserved
HX7LL motif that causes recruitment of Tab2 [7,8] was sufficient to mediate interaction with
Tab2(406–531). ERα(1–45) was expressed in bacteria as GST fusion protein and Tab2(406–531) was
in vitro transcribed and translated. As shown in Fig 2a, we observed that the ERα N-terminal
fragment (aa 1–45), but not GST alone, was sufficient to pull-down the Tab2 central domain.
One important point is whether this interaction exists in vivo. To ascertain this, we overex-
pressed T7-tagged Tab2(406–531) and p65-tagged ERα(1–60) in HEK293T cells and carried out
anti-T7 and anti-p65 immunoprecipitation from total cell lysates. We observed that
T7-Tab2(406–531) efficiently co-immunoprecipitated ERα(1–60), and vice-versa (Fig 2b), con-
firming the interaction between the central domain of Tab2 and the N-terminal region of ERα
also in living cells. The same experiment was carried out by overexpressing in HEK293T cells
the Flag-tagged full-length ERα: as shown in Fig 2c, also in this case the interaction was clearly
demonstrated.
The HX7LL motif present in the N-terminus of ERα is conserved in other steroid receptors,
among which PgR and AR, but not ERβ [7]. Therefore, we asked whether the central domain
of Tab2 was also able to interact with other receptors, specifically with AR that plays a role in
the response/resistance of prostate cancer cells to anti-androgenic drugs, in analogy to anti-
estrogens in breast cancer cells. To achieve this goal, we overexpressed T7-tagged Tab2(406–531)
and Flag-tagged full-length AR in HEK293T cells and carried out anti-T7 immunoprecipita-
tion from total cell lysates. We observed that T7-Tab2(406–531) co-immunoprecipitated full-
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length AR (Fig 2d). Thus, the central domain of Tab2 is responsible of the interaction of Tab2
with steroid receptors in general.
A Tab2 mimic peptide displaces the Tab2/ERα interaction
Taking advantage of the competition of in vitro transcribed and translated Tab2(406–531) in
Tab2/ERα interaction (Fig 1c), we further narrowed down the essential interaction motif
using a pull-down competition screening. To achieve this goal, 6 partially overlapping frag-
ments were designed on the sequence of the Tab2 central domain (S2b Fig), produced by PCR
and in vitro transcribed and translated. Competition of these peptides with Tab2/ERα interac-
tion was evaluated in pull-down assays using the recombinant protein MBP-Tab2(406–531) and
recombinant hERα (1 nM). The best competing fragment in this assay was Fragment 4 (S2a
Fig) representing aminoacids 471–504. This peptide also contains an LTNLL motif, structur-
ally interesting because potentially able to create an amphipathic α-helix that can be responsi-
ble of the interaction (S2 Fig). On the basis of these results, three partially overlapping 17-aa
synthetic peptides, corresponding to different portions of the above described Fragment 4,
thereafter called Tab2-pept1, Tab2-pept2 and Tab2-pept3, were synthesized (their sequences
are reported in Fig 3a). MBP pull-down assays, using MBP-Tab2(406–531) and recombinant
hERα (1 nM) were used to assay for the ability of these peptides to compete out the interaction.
As shown in Fig 3b, we observed that the synthetic Tab2-pept3, but not Tab2-pept1 nor
Tab2-pept2, was able to compete out efficiently the in vitro Tab2/ERα interaction. This data
indicate that the interacting motif is comprised within, or partly overlapping to, these 17-aa.
Interestingly, this peptide includes the LTNLL motif discussed above. A dose-response curve
demonstrated that Tab2-pept3 is already efficient in displacing the interaction at a concentra-
tion of 1 μM (Fig 3c).
A 17-aa Tab2 mimic peptide reduces the growth of MCF7 TamR cells in
the presence of Tamoxifen
Finally, we addressed the question whether such interfering peptide could relieve Tab2 inhibi-
tion of Tam response in cultured TamR cells, as we described for the ERα-derived peptide [8].
We fused Tab2-pept3 N-terminally to the minimized carrier sequence of the viral TAT pro-
tein, thus obtaining a cell permeable 26-aa peptide, called TAT-Tab2-pept3, and the corre-
sponding scrambled version (their sequences are shown in Fig 4a). To this purpose, we used
three different subcultures of clones of MCF7 TamR cells [16], in which Tam resistance was
shown to be dependent, at least in part, on Tab2 constitutive phosphorylation [8]. Cells were
treated with increasing concentrations (1 to 100 μM) of TAT-Tab2-pept3, or its scrambled ver-
sion, for 1 h in the absence of serum, then serum was added back and the effect on cell prolifer-
ation was measured 24 h later. Results of these experiments are shown in Fig 4b–4d. The effect
of peptide treatment was slightly different between TamR clones (TAMR-4 and TAMR-8) and
also among subcultures of the same clone (TAMR-4.1 and -4.2). TAT-Tab2-pept3 decreased
the growth of cells in the presence of 1 μM 4OHT in a dose-dependent fashion, with estimated
LD50 between 50–70 μM. The scrambled peptide also showed some inhibitory effect at the
highest concentrations, possibly due to toxic effect. Using a continuous-time autoregressive
model we observed a significant response in TAMR-4.1 (p<0.02), while in other cell lines
there was marginal significance. T-test analysis demonstrated at least one concentration point
with significant effect (see Fig 4 legend). The TAT-Tab2-pept3 had no effect on the growth of
cells cultured in absence of 4OHT (data not shown). These results further demonstrate that
interfering Tab2/ERα interaction may be exploited to revert in part Tamoxifen resistance in
breast cancer cells in vitro.
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Fig 4. A 17-aa Tab2 mimic peptide reduces the growth of MCF7-TamR cells in the presence of
Tamoxifen. a. Aminoacid sequences of Tab2-pept3 fused N-terminally to the minimized carrier sequence of
the viral TAT protein, and the scrambled version. b. MCF7-TamR cells were treated with increasing
concentration (1 to 100 μM) of TAT-Tab2-pept3 (∎) or its scrambled version (^) in absence of serum. After 1
hour, 1% DC-FBS and 10−6 M 4OHT were added and the effect on cell proliferation was measured 24 h later.
Data are means ± s.d. of triplicate experiments. Stars refer to significance of individual concentration points,
using T-test (* p<0.05; ** p<0.01). Continuous-time autoregressive model statistics gave p<0.02 for TAMR-
4.1 (b); p<0.09 for TAMR-4.2 (c); p<0.08 for TAMR-8 (d).
doi:10.1371/journal.pone.0168639.g004
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Discussion
The data presented here suggest that a central domain of Tab2 contains the major determi-
nants of the interaction with steroids receptors, thus providing a further annotation to this
multifunctional protein. We present evidence that a peptide mimicking aa. 480–496 of Tab2 is
able to compete efficiently with Tab2/ERα interaction in vitro, thus narrowing down the inter-
acting domain to a smaller region containing this motif (SRID = steroid receptor interacting
domain). In addition, we show that the corresponding cell-permeable peptide, TAT-Tab2-
pept3, reduces the growth of Tam-resistant breast cancer cells, cultured in the presence of
Tamoxifen, in a dose-dependent fashion. Thus, TAT-Tab2-pept3 together with the ERα-TAT
peptide previously identified [8] represent lead compounds to reverse Tam-resistance in breast
cancer cells. Moreover, considering that the central domain of Tab2 also interacts with AR
(and most likely with other steroid receptors sharing the same N-terminus), it represents a
promising tool for further pharmacological developments.
The SRID was not previously identified as a functional domain. It is embedded in a region
flanked on the C-terminal side by the CC-domain, which is supposed to provide a quite rigid
structure, and presenting a number of experimentally proven phosphorylation sites. In addi-
tion, within the minimal competing peptide (Tab2-pept3) the LTNLL motif may justify forma-
tion of an amphipathic α-helix that is frequently found in interacting protein surfaces. In
order to discuss the potential significance of the SRID, we have to consider the proposed
molecular mechanisms underlying Tab2-mediated derepression [7,17]. In this context, Tab2 is
recruited to genes that are repressed following antagonist treatment (either 4OHT in the case
of ERα or Bicalutamide in the case of AR) by direct interaction with the N-terminal domain of
steroid receptors. Since ERα/AR are antagonist-bound, they interact with NCoR rather than
coactivators [18,19]. Apparently, Tab2 is not necessary to this interaction, since its experimen-
tal down-regulation does not affect gene response to these drugs [7]. In the presence of signals
activating Tab2, i.e. either inflammatory signals or Receptor Tyrosine kinase activation or
other unidentified reasons as in TamR cells [8], Tab2 unveils its NES, dismisses interaction
with the steroid receptors, and translocates to the cytoplasm in complex with NCoR. Thus, the
Tab2/ERα interaction should be resolved following phosphorylation and parallels NES
unmasking. In this context, it is interesting to note that both the phosphorylation sites and the
NES are located very close to the identified SRID.
Tab2 NES (LQRELEI) is located in the CC region between aa 547–561. Site-directed muta-
genesis of the NES abrogated Tab2 translocation to the cytoplasm following phosphorylation
in response to IL-1β, also blocking NCoR export [5]. In the region spanning aa. 350 to 590, sev-
eral Ser/Thr phosphorylation sites are present [5,9–11,20] (as reported by the PhosphoSitePlus
resource www.phosphosite.org) and a particularly dense cluster is present between aa 413 and
484, that are phosphorylated following activation of kinase cascades involving MEKK1 and
p38, in response to cytokines and EGF. Ser419 and Ser423 are required for Tab2 export follow-
ing IL-1β [5,7]. It is relevant to note that Ser482 and Thr484 are included in the SRID (Fig 1a),
even though they were not identified as IL-1β-induced phosphorylation sites in the previously
cited study.
Given the density of phosphorylation sites around the SRID and the proximity of the NES,
it is tempting to speculate that phosphorylation may induce a conformational change in this
region, leading to steroid receptor dissociation and NES unmasking. In this context, it is
important to note that we did not get a “all-or-none” pattern in our mutants, suggesting that
other regions of Tab2 may be involved in steroid receptor binding, perhaps by stabilizing the
structure of this central domain.
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In the model of antagonist-bound AR or ERα, Tab2 may bind the steroid receptor and
NCoR at the same time. The interaction between Tab2 and NCoR has not been finely mapped:
it involves the repressor domain I of NCoR and the region of Tab2 comprising aa 1–628 [5,6],
i.e. all the protein with exclusion of the C-terminal NZF/zf-RanBP domain. Using the same in
vitro biochemical assay performed to study the Tab2/ERα interaction, and exploring all Tab2
fragments used in this work, we observed that the domain of Tab2 involved in NCoR binding
is proximal to its C-terminal region but outside the central domain interacting with ERα (data
not shown), thus allowing the hypothesis of contemporaneous complex.
Although this was not the primary objective of our work, we attempted a preliminary char-
acterization of the activity of Tab2 SRID in the context of antagonist drug resistance, in anal-
ogy to previously published data [8]. We obtained evidence that a cell-permeable peptide,
TAT-Tab2-pept3, that effectively competes with Tab2/ERα interaction in vitro, restores Tam
response in TamR breast cancer cells in a dose-dependent manner. Similar results were
obtained by treating the TamR cells with a peptide version containing carrier sequence of the
viral TAT protein at the C-term of the peptide (Tab2-pept3-TAT) (data not shown). It is
important to note that the growth reduction of TamR cells in the presence of Tam, is observed
at high concentrations of the peptide (75–100 μM) and further experiments will be necessary
to define the limits between effectiveness and toxicity of this peptide.
In conclusion, we have further refined the Tab2/ERα interaction, providing structural data
that can be exploited as a potential drug target for overcoming Tam resistance in breast cancer
cells or translated to other contexts in which activation of the inflammatory pathway cross-
talks and interferes with the response to steroid hormones.
Supporting Information
S1 Fig. Loading control for all Tab2 fragments used in MBP pull-down assays showed in
Fig 1b. All Tab2 fragments are MBP fusion proteins, thus the western blot was analyzed with
anti-MBP antibody. The stars () denote bands corresponding to the Tab2 fragments indicated
at the top of the lanes.
(TIF)
S2 Fig. Pull-down competition screening of Tab2(406–531) fragments. a. The recombinant
protein MBP-Tab2(406–531) and recombinant hERα (1 nM) in the presence or not of the in
vitro transcribed and translated 6 partially overlapping fragments on the sequence of the Tab2
central fragment 406–531 were used. Input = loading control for recombinant hERα. b. Ami-
noacid sequences of the 6 partially overlapping fragments designed on the sequence of
Tab2(406–531). In fragment 4 the LTNLL sequence is shown in bold. Displacing activity = ability
in interfering in Tab2/ERα interaction.
(TIF)
S3 Fig. Original blots for Fig 1b.
(TIF)
S4 Fig. Original blots for Fig 1c.
(TIF)
S5 Fig. Original blots for Fig 2a.
(TIF)
S6 Fig. Original blots for Fig 2b, 2c and 2d.
(TIF)
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S7 Fig. Original blots for S2a Fig.
(TIF)
S8 Fig. Original blots for Fig 3b.
(TIF)
S9 Fig. Original blots for Fig 3c.
(TIF)
S10 Fig. Effect of TAT-Tab2-pept3 in the presence or absence of 4OHT. MCF7-TAMR-4.2
cells were treated with 75 μM TAT-Tab2-pept3 (black bars) or its scrambled version (gray
bars) in the absence of serum. After 1 hour, 1% DC-FBS plus or minus 10−6 M 4OHT were
added and the effect on cell proliferation was measured 24 h later. Data are means ± S.D. of
cell growth evaluation in pentaplicate referred to a single representative experiment.
(TIF)
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